Genmab A (GMAB) Long-Term Deferred Tax (2023 - 2025)

Genmab A's Long-Term Deferred Tax history spans 3 years, with the latest figure at $171.0 million for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 34.65% year-over-year to $171.0 million; the TTM value through Dec 2025 reached $171.0 million, up 34.65%, while the annual FY2025 figure was $171.0 million, 34.65% up from the prior year.
  • Long-Term Deferred Tax reached $171.0 million in Q4 2025 per GMAB's latest filing, up from $127.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $171.0 million in Q4 2025 to a low of $31.0 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $109.7 million, with a median of $127.0 million recorded in 2024.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 309.68% in 2024, then skyrocketed 34.65% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $31.0 million in 2023, then surged by 309.68% to $127.0 million in 2024, then surged by 34.65% to $171.0 million in 2025.
  • Per Business Quant, the three most recent readings for GMAB's Long-Term Deferred Tax are $171.0 million (Q4 2025), $127.0 million (Q4 2024), and $31.0 million (Q4 2023).